Kisqali (ribociclib)

News alerts, weekly reports and conference planners

Company:

Novartis, Otsuka

Drug class:

CDK4 inhibitor, CDK6 inhibitor

Related drugs:

PIK3CA mutation	Colorectal Cancer	PIK3CA mutation	Colorectal Cancer	alpelisib + ribociclib Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks (New D) alpelisib + ribociclib Sensitive : D ASCO-GI 2023 - 2wk	alpelisib + ribociclib Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks alpelisib + ribociclib Sensitive : D ASCO-GI 2023 - 2 weeks - (New D)
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	alpelisib + ribociclib Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks (New D) alpelisib + ribociclib Sensitive : D ASCO-GI 2023 - 2wk	alpelisib + ribociclib Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks alpelisib + ribociclib Sensitive : D ASCO-GI 2023 - 2 weeks - (New D)
PIK3CA mutation + KRAS mutation	Colorectal Cancer	PIK3CA mutation + KRAS mutation	Colorectal Cancer	alpelisib + ribociclib Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks (New D) alpelisib + ribociclib Sensitive : D ASCO-GI 2023 - 2wk	alpelisib + ribociclib Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks alpelisib + ribociclib Sensitive : D ASCO-GI 2023 - 2 weeks - (New D)
PIK3CA wild-type + KRAS wild-type	Colorectal Cancer	PIK3CA wild-type + KRAS wild-type	Colorectal Cancer	alpelisib + ribociclib Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks (New D) alpelisib + ribociclib Sensitive : D ASCO-GI 2023 - 2wk	alpelisib + ribociclib Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks alpelisib + ribociclib Sensitive : D ASCO-GI 2023 - 2 weeks - (New D)
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	ribociclib Sensitive: A1 - Approval ribociclib Sensitive : A1	ribociclib Sensitive: A1 - Approval ribociclib Sensitive : A1
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	ribociclib Sensitive: A1 - Approval ribociclib Sensitive : A1	ribociclib Sensitive: A1 - Approval ribociclib Sensitive : A1
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	ribociclib Sensitive: A2 - Guideline ribociclib Sensitive : A2	ribociclib Sensitive: A2 - Guideline ribociclib Sensitive : A2
ER positive + PGR negative + HER-2 negative	HER2 Negative Breast Cancer	ER positive + PGR negative + HER-2 negative	HER2 Negative Breast Cancer	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B
HER-2 mutation	Breast Cancer	HER-2 mutation	Breast Cancer	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B
AKT1 mutation	Breast Cancer	AKT1 mutation	Breast Cancer	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B
BRCA1 mutation	Breast Cancer	BRCA1 mutation	Breast Cancer	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B
BRCA2 mutation	Breast Cancer	BRCA2 mutation	Breast Cancer	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B
ATM mutation	Breast Cancer	ATM mutation	Breast Cancer	ribociclib Resistant: B - Late Trials ribociclib Resistant : B	ribociclib Resistant: B - Late Trials ribociclib Resistant : B
CDKN2A mutation	Breast Cancer	CDKN2A mutation	Breast Cancer	ribociclib Resistant: B - Late Trials ribociclib Resistant : B	ribociclib Resistant: B - Late Trials ribociclib Resistant : B
FRS2 mutation	Breast Cancer	FRS2 mutation	Breast Cancer	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B
MDM2 mutation	Breast Cancer	MDM2 mutation	Breast Cancer	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B
PRKCA mutation	Breast Cancer	PRKCA mutation	Breast Cancer	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B
CHD4 mutation	Breast Cancer	CHD4 mutation	Breast Cancer	ribociclib Resistant: B - Late Trials ribociclib Resistant : B	ribociclib Resistant: B - Late Trials ribociclib Resistant : B
BCL11B mutation	Breast Cancer	BCL11B mutation	Breast Cancer	ribociclib Resistant: B - Late Trials ribociclib Resistant : B	ribociclib Resistant: B - Late Trials ribociclib Resistant : B
CDKN2B mutation	Breast Cancer	CDKN2B mutation	Breast Cancer	ribociclib Resistant: B - Late Trials ribociclib Resistant : B	ribociclib Resistant: B - Late Trials ribociclib Resistant : B
CDKN2C mutation	Breast Cancer	CDKN2C mutation	Breast Cancer	ribociclib Resistant: B - Late Trials ribociclib Resistant : B	ribociclib Resistant: B - Late Trials ribociclib Resistant : B
HR positive + HER-2 negative	Male Breast Cancer	HR positive + HER-2 negative	Male Breast Cancer	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B
ER positive	Ovarian Cancer	ER positive	Ovarian Cancer	ribociclib Sensitive: C2 – Inclusion Criteria ribociclib Sensitive : C2	ribociclib Sensitive: C2 – Inclusion Criteria ribociclib Sensitive : C2
ER positive	Endometrial Cancer	ER positive	Endometrial Cancer	ribociclib + letrozole Sensitive: C2 – Inclusion Criteria ribociclib + letrozole Sensitive : C2	ribociclib + letrozole Sensitive: C2 – Inclusion Criteria ribociclib + letrozole Sensitive : C2
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	ribociclib Sensitive: C2 – Inclusion Criteria ribociclib Sensitive : C2	ribociclib Sensitive: C2 – Inclusion Criteria ribociclib Sensitive : C2
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	ceritinib + ribociclib Sensitive: C2 – Inclusion Criteria ceritinib + ribociclib Sensitive : C2	ceritinib + ribociclib Sensitive: C2 – Inclusion Criteria ceritinib + ribociclib Sensitive : C2
TYMS overexpression + HR positive	HER2 Negative Breast Cancer	TYMS overexpression + HR positive	HER2 Negative Breast Cancer	ribociclib Sensitive: C3 – Early Trials ribociclib Sensitive : C3	ribociclib Sensitive: C3 – Early Trials ribociclib Sensitive : C3
FGFR1 overexpression + HR positive	HER2 Negative Breast Cancer	FGFR1 overexpression + HR positive	HER2 Negative Breast Cancer	ribociclib Sensitive: C3 – Early Trials ribociclib Sensitive : C3	ribociclib Sensitive: C3 – Early Trials ribociclib Sensitive : C3
PIK3CA mutation	Breast Cancer	PIK3CA mutation	Breast Cancer	ribociclib Sensitive: C3 – Early Trials ribociclib Sensitive : C3	ribociclib Sensitive: C3 – Early Trials ribociclib Sensitive : C3
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	ribociclib + AN2025 Sensitive: C3 – Early Trials ribociclib + AN2025 Sensitive : C3	ribociclib + AN2025 Sensitive: C3 – Early Trials ribociclib + AN2025 Sensitive : C3
CCND1 amplification	Melanoma	CCND1 amplification	Melanoma	ribociclib Sensitive: C3 – Early Trials ribociclib Sensitive : C3	ribociclib Sensitive: C3 – Early Trials ribociclib Sensitive : C3
NRAS mutation	Melanoma	NRAS mutation	Melanoma	binimetinib + ribociclib Sensitive: C3 – Early Trials binimetinib + ribociclib Sensitive : C3	binimetinib + ribociclib Sensitive: C3 – Early Trials binimetinib + ribociclib Sensitive : C3
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	everolimus + ribociclib Sensitive: C3 – Early Trials everolimus + ribociclib Sensitive : C3	everolimus + ribociclib Sensitive: C3 – Early Trials everolimus + ribociclib Sensitive : C3
HER-2 mutation + CDK6 mutation	Ampulla of Vater Carcinoma	HER-2 mutation + CDK6 mutation	Ampulla of Vater Carcinoma	palbociclib + pertuzumab + abemaciclib + ribociclib + trastuzumab/hyaluronidase-oysk Sensitive: C3 – Early Trials palbociclib + pertuzumab + abemaciclib + ribociclib + trastuzumab / hyaluronidase-oysk Sensitive : C3	palbociclib + pertuzumab + abemaciclib + ribociclib + trastuzumab/hyaluronidase-oysk Sensitive: C3 – Early Trials palbociclib + pertuzumab + abemaciclib + ribociclib + trastuzumab / hyaluronidase-oysk Sensitive : C3
CDKN2A deletion	Estrogen Receptor Positive Breast Cancer	CDKN2A deletion	Estrogen Receptor Positive Breast Cancer	ribociclib + VRx-510 Sensitive: D – Preclinical ribociclib + VRx-510 Sensitive : D	ribociclib + VRx-510 Sensitive: D – Preclinical ribociclib + VRx-510 Sensitive : D

Kisqali (ribociclib)

Associations
(55)

Associations
(55)

Kisqali (ribociclib)

Associations(55)

Associations(55)

Associations
(55)

Associations
(55)